- Home
- BFRI vs IMRN Comparison
BFRI vs IMRN Comparison
Compare BFRI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- IMRN
- Stock Information
- Founded
- BFRI 1997
- IMRN 1994
- Country
- BFRI United States
- IMRN Australia
- Employees
- BFRI N/A
- IMRN N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- IMRN Health Care
- Exchange
- BFRI Nasdaq
- IMRN Nasdaq
- Market Cap
- BFRI 8.7M
- IMRN 10.1M
- IPO Year
- BFRI 2021
- IMRN N/A
- Fundamental
- Price
- BFRI $0.80
- IMRN $1.75
- Analyst Decision
- BFRI Strong Buy
- IMRN Strong Buy
- Analyst Count
- BFRI 1
- IMRN 1
- Target Price
- BFRI $7.00
- IMRN $5.00
- AVG Volume (30 Days)
- BFRI 90.7K
- IMRN 13.6K
- Earning Date
- BFRI 03-21-2025
- IMRN 04-08-2025
- Dividend Yield
- BFRI N/A
- IMRN N/A
- EPS Growth
- BFRI N/A
- IMRN N/A
- EPS
- BFRI N/A
- IMRN N/A
- Revenue
- BFRI $37,321,000.00
- IMRN $4,048,286.00
- Revenue This Year
- BFRI $28.62
- IMRN N/A
- Revenue Next Year
- BFRI $27.07
- IMRN N/A
- P/E Ratio
- BFRI N/A
- IMRN N/A
- Revenue Growth
- BFRI 9.54
- IMRN 82.90
- 52 Week Low
- BFRI $0.65
- IMRN $1.70
- 52 Week High
- BFRI $2.43
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- BFRI 34.75
- IMRN 41.07
- Support Level
- BFRI $0.81
- IMRN $1.73
- Resistance Level
- BFRI $0.96
- IMRN $2.10
- Average True Range (ATR)
- BFRI 0.08
- IMRN 0.12
- MACD
- BFRI -0.01
- IMRN 0.01
- Stochastic Oscillator
- BFRI 8.79
- IMRN 10.26
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.